Occidental Asset Management LLC lifted its stake in shares of Quest Diagnostics Inc (NYSE:DGX) by 5.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,340 shares of the medical research company’s stock after buying an additional 520 shares during the period. Occidental Asset Management LLC’s holdings in Quest Diagnostics were worth $997,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Signaturefd LLC lifted its stake in shares of Quest Diagnostics by 15.9% during the third quarter. Signaturefd LLC now owns 714 shares of the medical research company’s stock worth $76,000 after buying an additional 98 shares during the period. Acropolis Investment Management LLC lifted its stake in shares of Quest Diagnostics by 2.2% during the third quarter. Acropolis Investment Management LLC now owns 4,700 shares of the medical research company’s stock worth $503,000 after buying an additional 100 shares during the period. Commerzbank Aktiengesellschaft FI lifted its stake in shares of Quest Diagnostics by 2.9% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 3,661 shares of the medical research company’s stock worth $392,000 after buying an additional 103 shares during the period. United Capital Financial Advisers LLC lifted its stake in shares of Quest Diagnostics by 0.5% during the second quarter. United Capital Financial Advisers LLC now owns 21,547 shares of the medical research company’s stock worth $2,194,000 after buying an additional 108 shares during the period. Finally, OLD National Bancorp IN raised its holdings in shares of Quest Diagnostics by 1.6% during the third quarter. OLD National Bancorp IN now owns 7,170 shares of the medical research company’s stock worth $767,000 after purchasing an additional 111 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

In other news, Director Gail R. Wilensky sold 8,000 shares of Quest Diagnostics stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $107.17, for a total value of $857,360.00. Following the sale, the director now owns 22,951 shares in the company, valued at $2,459,658.67. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael E. Prevoznik sold 44,556 shares of Quest Diagnostics stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $107.43, for a total transaction of $4,786,651.08. Following the completion of the sale, the senior vice president now owns 51,321 shares in the company, valued at approximately $5,513,415.03. The disclosure for this sale can be found here. 1.86% of the stock is currently owned by insiders.

Several research analysts recently issued reports on the stock. Wells Fargo & Co assumed coverage on shares of Quest Diagnostics in a report on Tuesday, January 7th. They set an “underweight” rating and a $100.00 target price for the company. UBS Group reduced their target price on shares of Quest Diagnostics from $103.00 to $102.00 and set a “neutral” rating for the company in a report on Monday, October 21st. Zacks Investment Research raised shares of Quest Diagnostics from a “sell” rating to a “hold” rating and set a $111.00 target price for the company in a report on Monday, September 30th. Barclays cut shares of Quest Diagnostics from an “overweight” rating to an “equal weight” rating and set a $106.00 target price for the company. in a report on Tuesday, January 7th. Finally, ValuEngine cut shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, November 29th. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. Quest Diagnostics has a consensus rating of “Hold” and an average target price of $106.07.

DGX opened at $106.73 on Thursday. Quest Diagnostics Inc has a fifty-two week low of $82.59 and a fifty-two week high of $108.95. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.83 and a current ratio of 0.88. The company has a fifty day moving average of $106.33 and a two-hundred day moving average of $103.69. The stock has a market capitalization of $14.38 billion, a price-to-earnings ratio of 16.91, a PEG ratio of 2.09 and a beta of 0.85.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Tuesday, October 22nd. The medical research company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.71 by $0.05. Quest Diagnostics had a net margin of 9.58% and a return on equity of 15.32%. The company had revenue of $1.96 billion during the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter in the previous year, the company earned $1.68 earnings per share. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, equities research analysts forecast that Quest Diagnostics Inc will post 6.49 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 29th. Shareholders of record on Tuesday, January 14th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, January 13th. This represents a $2.12 dividend on an annualized basis and a yield of 1.99%. Quest Diagnostics’s payout ratio is 33.60%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.